Publication

Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.

Journal Paper/Review - Feb 9, 2023

Units
PubMed
Doi
Contact

Citation
Çakar E, Oniangue-Ndza C, Schneider R, Klijn S, Vogl U, Rothermundt C, May J. Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland. Pharmacoecon Open 2023
Type
Journal Paper/Review (English)
Journal
Pharmacoecon Open 2023
Publication Date
Feb 9, 2023
Issn Electronic
2509-4254
Brief description/objective

This study assessed the cost-effectiveness of nivolumab plus ipilimumab versus both sunitinib and pazopanib for the treatment of first-line unresectable advanced renal cell carcinoma (aRCC) from a healthcare system perspective in Switzerland.